arrow
I

Iris Palme

Heidelberg University
H指数:7
被引数:257

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Primary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243

具有空泡的E1酶、X连锁、自身炎症性、体细胞(VEXAS)综合征患者的外周CD34+细胞对TAK-243靶向治疗高度敏感。

2025-10-120
OAAI
Machine learning-based in-silico analysis identifies signatures of lysyl oxidases for prognostic and therapeutic response prediction in cancer

基于机器学习的计算机分析可识别赖氨酰氧化酶的特征,以预测癌症的预后和治疗反应

2025-04-050
OAAI
Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

Vexas患者的原发性造血细胞对TAK-243和Pevonedistat治疗高度敏感

BLOOD
IF23.1
2024-11-050
PRE
Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms
2024-02-271
OAAI
ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms
2023-11-022
OAAI
Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium
2023-06-075
OAAI
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
2023-03-175
OAAI
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
LEUKEMIA
IF13.4
2021-06-258
OAAI
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations
2020-09-1428
OAAI
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA
2017-06-090
OAAI